- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01999023
Effects of Low Protein Formula on Renal Function, Oxidative Stress and Antioxidant Capacities in CKD Patients
November 25, 2013 updated by: Taichung Veterans General Hospital
The Effects of Low Protein Formula on Renal Function, Oxidative Stress and Antioxidant Capacities in Patients With Chronic Kidney Disease
Chronic renal disease is now the tenth leading cause of mortality Taiwan.
It is worth to study the effect of low protein formula on the retardation of failing renal function, decrease plasma homocysteine and oxidative stress and further increase antioxidant capacities in patients with chronic kidney disease.
The purpose of this study is going to investigate the effects of protein formula on renal function, homocysteine , oxidative stress and antioxidant capacities in patients with chronic kidney disease.
One hundred and twenty patients with end stage renal disease (stage 2~4) who meet the inclusion criteria will be recruited from Taichung General Veterans Hospital, Taichung.
Participant patients will be blinded and randomly assigned to either the placebo (n = 60) or low protein formula (n = 60) for 12 weeks.
Data on demography, anthropometry and medical history will be collected, and fasting blood samples and 24 h urine samples will be obtained at week 0, 12 and 24 during intervention period.
The levels of hematological, plasma and erythrocyte PLP, plasma pyridoxal and 4-pyridoxic acid, serum and erythrocyte folate, serum vitamin B-12, homocysteine, lipid peroxidation indicators, glutathione, total antioxidant capacity and antioxidant enzymatic will be measured.
Twenty-four hour urine volume will be recorded and urine creatinine and urea nitrogen will be analyzed.
Creatinine clearance rate will be measured.
Hopefully, the results of this study could provide more pictures on beneficial effects of low protein formula on renal function, plasma homocysteine, oxidative stress and antioxidant capacities in patients with chronic kidney disease.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Chronic renal disease is now the tenth leading cause of mortality Taiwan.
It is worth to study the effect of low protein formula on the retardation of failing renal function, decrease plasma homocysteine and oxidative stress and further increase antioxidant capacities in patients with chronic kidney disease.
The purpose of this study is going to investigate the effects of protein formula on renal function, homocysteine , oxidative stress and antioxidant capacities in patients with chronic kidney disease.
This protocol is designed as a hospital-based blinded randomized placebo-controlled intervention trial.
One hundred and twenty patients with end stage renal disease who meet the inclusion criteria will be recruited from Taichung General Veterans Hospital, Taichung.
Participant patients will be blinded and randomly assigned to either the placebo (n = 60) or low protein formula (n = 60) for 12 weeks.
Data on demography, anthropometry and medical history will be collected, and fasting blood samples and 24 h urine samples will be obtained at week 0, 12 and 24 during intervention period.
The levels of hematological (red blood cell, hemoglobin, albumin, creatinine, urea nitrogen, total cholesterol, triglyceride, high and low density lipoprotein), plasma and erythrocyte PLP, plasma pyridoxal and 4-pyridoxic acid, serum and erythrocyte folate, serum vitamin B-12, homocysteine, lipid peroxidation indicators (serum malondialdehyde and oxidized low density lipoprotein), glutathione, total antioxidant capacity and antioxidant enzymatic activities (superoxide dismutase, glutathione peroxidase, glutathione S-transferase, glutathione reductase) will be measured.
Twenty-four hour urine volume will be recorded and urine creatinine and urea nitrogen will be analyzed.
Creatinine clearance rate will be measured.
Hopefully, the results of this study could provide more pictures on beneficial effects of low protein formula on renal function, plasma homocysteine, oxidative stress and antioxidant capacities in patients with chronic kidney disease.
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 81 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
1) Diagnosed as stage 2 ~ 3 chronic kidney disease
Exclusion Criteria:
- clinical unstable (i.e., systolic blood pressure < 90 mmHg, mean arterial blood pressure < 65 mmHg, fatal arrhythmia or the requirement of vasopressor to maintain blood pressure) or unconscious at any point during the study.
- chronic diseases (i.e. liver disease, gastrointestinal diseases, alcoholism, cancer); or 3) being in pregnant or lactation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Observational group
No intervention
|
|
|
Experimental: Dietary supplement
Low protein formula formula (28.5 g) twice a day
|
Low protein formula formula (28.5 g) twice a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Creatinine clearance rate
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (Anticipated)
December 1, 2014
Study Completion (Anticipated)
December 1, 2014
Study Registration Dates
First Submitted
November 20, 2013
First Submitted That Met QC Criteria
November 25, 2013
First Posted (Estimate)
December 3, 2013
Study Record Updates
Last Update Posted (Estimate)
December 3, 2013
Last Update Submitted That Met QC Criteria
November 25, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SF13223
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Renal Disease
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
Marcela Cangussu BarbalhoHospital Universitário Cassiano Antônio MoraesRecruiting
-
Novartis PharmaceuticalsCompletedEnd-Stage Renal Disease | Renal Failure, ChronicGermany
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedChronic Renal Disease | Renal DialysisBrazil
-
University of MichiganTheravance BiopharmaCompletedEnd-Stage Renal Disease | Stage 5 Chronic Kidney DiseaseUnited States
-
Novartis PharmaceuticalsCompletedHemodialysis | Renal Replacement Therapy | End Stage Renal Disease (ESRD) | Renal Transplantation | Chronic Kidney Disease (CKD)Germany, United States, Belgium, Italy, Spain, Croatia, Taiwan, Australia, Austria, Greece, Korea, Republic of, Lebanon, Czechia, Israel, Netherlands, Slovenia, Switzerland, Thailand, Norway, Turkey, Sweden, Argentina, Brazil, Japan, Se... and more
-
Cubist Pharmaceuticals LLCCompletedEnd-stage Renal Disease | Renal Failure Chronic Requiring HemodialysisUnited States
-
Novo Nordisk A/SCompletedHealthy | Chronic Kidney Disease | End-Stage Renal DiseaseGermany
-
ArdelyxAstraZenecaCompletedEnd Stage Renal Disease | ESRD | Chronic Kidney Disease Stage 5United States
Clinical Trials on Low protein formula group
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Humana Co.Ltd.CompletedSafety Issues | Infant Nutrition DisordersItaly
-
Société des Produits Nestlé (SPN)Completed
-
University of CologneCompletedChronic Kidney DiseaseGermany
-
HiPP GmbH & Co. Vertrieb KGBiofortis, Merieux NutriSciences; Waldkrankenhaus Protestant Hospital, Spandau and other collaboratorsCompleted
-
Société des Produits Nestlé (SPN)Completed
-
Ludwig-Maximilians - University of MunichEuropean UnionActive, not recruitingInfant DevelopmentBelgium, Germany, Italy, Poland, Spain
-
Oslo University HospitalCompletedSmoking | Obesity | OverweightNorway
-
University of NottinghamChenot Group, HC International SACompleted
-
Children's Hospital of Fudan UniversityCompleted
-
Ruijin HospitalChengdu Women's and Children's Central Hospital; Zhengzhou Children's Hospital... and other collaboratorsNot yet recruitingMild Allergic Symptoms in Infants | Infant Feeding Intolerance